SOURCE: BIOLASE Technology, Inc.

September 16, 2008 06:00 ET

BIOLASE Receives New Patent Covering Core Laser Plus Water Technology

IRVINE, CA--(Marketwire - September 16, 2008) - BIOLASE Technology, Inc. (NASDAQ: BLTI) today announced that it has been granted a new U.S. patent related to the core laser plus water technology that is central to current and future dental laser generations. Specifically, the coverage provides for use of electromagnetic energy (e.g. laser) with fluid (e.g. water) that has at least one output micropulse (e.g. Er, Cr:YSGG, Er:YAG, etc.) to allow the cutting of tissue. Additional claims included in the allowance cover specific lasers and tissues.

BIOLASE CEO Jake St. Philip said that this new patent further strengthens the Company's intellectual property position, which remains a top priority for the Company.

"This patent covers important apparatus and methods currently integrated into our core products, and it also protects future technologies that we plan to use in next-generation laser devices. We have focused a significant amount of energy on improving our execution, controlling costs, building a solid operating foundation, and introducing new products and product enhancements. Our continued focus on research and development is another core component to our long-term goals of continued steady growth," St. Philip added.

The patent, No. 7,415,050, has broad coverage through both method and apparatus claims. The patent contains 19 claims, of which two are independent.

About BIOLASE Technology, Inc.

BIOLASE Technology, Inc. (http://www.biolase.com), the world's leading dental laser company, develops, manufactures and markets lasers and related products that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

Contact Information

  • For further information, contact:
    David M. Mulder
    Chief Financial Officer
    BIOLASE Technology, Inc.
    +1-949-361-1200

    Jill Bertotti
    Allen & Caron
    +1-949-474-4300